Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | CASP1 | P29466 | 1/20 | 0.96 |
| ▸ | CASP7 | P55210 | 1/20 | 0.96 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115677 | 0.98 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL29455006 | 0.98 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL475177 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL1567458 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| Hydrochloric Acid SCHEMBL10445772 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL4729030 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL3680114 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL8584630 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL17580296 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| Methane SCHEMBL27562791 | 0.96 | ALDH1A1 (0.96) | ALDH1A1MEN1KMT2ACASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028347-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250353855-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | disclosed |
| US-20240132509-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028347-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 1288/4885MEN1 1647/4885KMT2A 2554/4885 |
| US-20240132509-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HCN3, TRPV1 | ALDH1A1 3961/4885MEN1 4311/4885KMT2A 1843/4885 |
| US-20250353855-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | ALDH1A1 1719/4885MEN1 1477/4885KMT2A 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.